Cross-Taper Strategy: Rexulti 1mg to Risperidone 0.25mg
Use gradual cross-titration over 1-2 weeks, starting risperidone 0.25mg while maintaining Rexulti 1mg initially, then tapering Rexulti by 0.5mg every 3-7 days while monitoring for withdrawal symptoms and psychotic symptom re-emergence. 1
Recommended Cross-Titration Schedule
The 2025 INTEGRATE guidelines explicitly state that antipsychotic switching should involve gradual cross-titration informed by the half-life and receptor profile of each medication 1. Given that brexpiprazole (Rexulti) is a D2 partial agonist and risperidone is a D2 antagonist with different pharmacodynamic profiles, overlapping is essential.
Week 1 Approach:
- Days 1-3: Continue Rexulti 1mg, add risperidone 0.25mg
- Days 4-7: Reduce Rexulti to 0.5mg, continue risperidone 0.25mg
Week 2 Approach:
- Days 8-10: Reduce Rexulti to 0.25mg, continue risperidone 0.25mg
- Days 11-14: Discontinue Rexulti, continue risperidone 0.25mg alone
Critical Pharmacological Considerations
Brexpiprazole has a long half-life (approximately 91 hours) 2, meaning it will remain in the system for several days after discontinuation. This provides some buffer against abrupt dopamine receptor changes but also means you need to monitor for overlapping effects during the cross-taper.
The switch from a D2 partial agonist (brexpiprazole) to a D2 antagonist (risperidone) represents a significant pharmacodynamic shift 1. Research specifically examining brexpiprazole switches demonstrated high medication persistence rates (78.5% at 12 weeks) when using plateau cross-titration methods 3.
Monitoring Requirements
Watch closely for:
- Withdrawal symptoms: Insomnia, nausea, anxiety, agitation, or rebound psychosis 4
- Extrapyramidal symptoms: Risperidone carries higher EPS risk than brexpiprazole
- Prolactin elevation: Risperidone significantly elevates prolactin while brexpiprazole is prolactin-sparing 5
- Re-emergence of positive symptoms: Assess weekly during the transition 1
Important Caveats
The risperidone dose of 0.25mg is extremely low and may be subtherapeutic for most patients with schizophrenia. If this switch is for agitation in dementia or dose reduction purposes, this makes more sense. However, if treating schizophrenia, you will likely need to titrate risperidone higher (typical range 2-6mg daily) after completing the cross-taper 1.
Abrupt switching is generally not recommended unless there's a severe adverse reaction requiring immediate discontinuation 4, 6. The overlapping method minimizes discontinuation reactions while maintaining antipsychotic coverage.
The cross-titration can be accelerated (completed in 7 days instead of 14) if the patient tolerates the initial overlap well and shows no withdrawal symptoms, but slower is safer for most patients 6.